Earnings Summary

Acadia Pharmaceuticals Inc.’s revenue jumped 69.27% since last year same period to $231.04Mn in the Q4 2023. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated 9.14% jump in its revenue since last 3-months.

Acadia Pharmaceuticals Inc.’s net profit jumped 209.76% since last year same period to $45.8Mn in the Q4 2023. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated 170.27% jump in its net profits since last 3-months.

Acadia Pharmaceuticals Inc.’s net profit margin jumped 164.84% since last year same period to 19.82% in the Q4 2023. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated 164.38% jump in its net profit margins since last 3-months.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.05 - a -83.33% fall from last quarter’s estimates.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current year stand at 0.05.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) jumped 207.69% since last year same period to 0.28 in the Q4 2023. This indicates that the Acadia Pharmaceuticals Inc. has generated 207.69% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Acadia Pharmaceuticals Inc.’s return on assets (ROA) stands at -0.07.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Acadia Pharmaceuticals Inc.’s return on equity (ROE) stands at -0.15.